Cited 101 times in
Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김진석 | - |
dc.contributor.author | 양우익 | - |
dc.date.accessioned | 2014-12-19T16:47:15Z | - |
dc.date.available | 2014-12-19T16:47:15Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0959-8049 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/90193 | - |
dc.description.abstract | BACKGROUND: We performed a phase II study to evaluate the efficacy of bortezomib in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas (PTCLs) based on our phase I study results. METHODS: Patients received bortezomib on days 1 and 8 at a dose of 1.6 mg/m(2) in addition to CHOP every 3 weeks for a total of six cycles. RESULTS: Forty-six patients were enrolled: PTCL, not otherwise specified (PTCL-NOS, n=16), extranodal NK/T-cell lymphoma, nasal type (ENKTL, n=10), angioimmunoblastic T-cell lymphoma (AITL, n=8), ALK-negative anaplastic large-cell lymphoma (ALCL, n=6), cutaneous T-cell lymphoma (CTCL, n=5) and hepatosplenic T-cell lymphoma (n=1). Thirty patients achieved complete response (CR, 65%) and the overall response rate was 76% (35/46). Although the CR rate of ENKTL was only 30% (3/10), three subtypes of PTCLs (PTCL-NOS, AITL and ALCL) showed 87% of overall response rate (ORR) (26/30) and 73% of CR rate (22/30). However, the 3-year overall survival and progression-free survival were 47% and 35%, respectively due to frequent relapse after remission. Grade 3/4 leucopenia was the most frequent toxicity whereas neurotoxicity was tolerable: grade 1 or 2 of peripheral neuropathy. CONCLUSIONS: The combined treatment of bortezomib and CHOP is an effective and feasible regimen for advanced-stage PTCLs other than ENKTL, with acceptable toxicity. However, future studies exploring new drug combinations are warranted to overcome relapse after remission. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | EUROPEAN JOURNAL OF CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/administration & dosage | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Boronic Acids/administration & dosage | - |
dc.subject.MESH | Boronic Acids/adverse effects | - |
dc.subject.MESH | Bortezomib | - |
dc.subject.MESH | Cyclophosphamide/administration & dosage | - |
dc.subject.MESH | Cyclophosphamide/adverse effects | - |
dc.subject.MESH | Doxorubicin/administration & dosage | - |
dc.subject.MESH | Doxorubicin/adverse effects | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lymphoma, T-Cell, Peripheral/drug therapy* | - |
dc.subject.MESH | Lymphoma, T-Cell, Peripheral/mortality | - |
dc.subject.MESH | Lymphoma, T-Cell, Peripheral/pathology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | NF-kappa B/metabolism | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Prednisone/administration & dosage | - |
dc.subject.MESH | Prednisone/adverse effects | - |
dc.subject.MESH | Pyrazines/administration & dosage | - |
dc.subject.MESH | Pyrazines/adverse effects | - |
dc.subject.MESH | Vincristine/administration & dosage | - |
dc.subject.MESH | Vincristine/adverse effects | - |
dc.title | Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pathology (병리학) | - |
dc.contributor.googleauthor | Seok Jin Kim | - |
dc.contributor.googleauthor | Dok Hyun Yoon | - |
dc.contributor.googleauthor | Hye Jin Kang | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.contributor.googleauthor | Seong Kyu Park | - |
dc.contributor.googleauthor | Hyo Jung Kim | - |
dc.contributor.googleauthor | Jeeyun Lee | - |
dc.contributor.googleauthor | Baek-Yeol Ryoo | - |
dc.contributor.googleauthor | Young Hyeh Ko | - |
dc.contributor.googleauthor | Jooryung Huh | - |
dc.contributor.googleauthor | Woo Ick Yang | - |
dc.contributor.googleauthor | Hee Kyung Kim | - |
dc.contributor.googleauthor | Soo Kee Min | - |
dc.contributor.googleauthor | Seung-Sook Lee | - |
dc.contributor.googleauthor | In-Gu Do | - |
dc.contributor.googleauthor | Cheolwon Suh | - |
dc.contributor.googleauthor | Won Seog Kim | - |
dc.identifier.doi | 10.1016/j.ejca.2012.06.003 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01017 | - |
dc.contributor.localId | A02300 | - |
dc.relation.journalcode | J00809 | - |
dc.identifier.eissn | 1879-0852 | - |
dc.identifier.pmid | 22770877 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S095980491200473X | - |
dc.subject.keyword | Bortezomib | - |
dc.subject.keyword | CHOP | - |
dc.subject.keyword | Peripheral T-cell lymphoma | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.alternativeName | Yang, Woo Ick | - |
dc.contributor.affiliatedAuthor | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | Yang, Woo Ick | - |
dc.citation.volume | 48 | - |
dc.citation.number | 17 | - |
dc.citation.startPage | 3223 | - |
dc.citation.endPage | 3231 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF CANCER, Vol.48(17) : 3223-3231, 2012 | - |
dc.identifier.rimsid | 32417 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.